 |
|
Recent advances in nonalcoholic fatty liver disease metabolomics
Hwi Young Kim
Clin Mol Hepatol. 2021;27(4):553-559. Published online 2021 Jun 8 DOI: https://doi.org/10.3350/cmh.2021.0127
|
|
Citations to this article as recorded by
 Enhanced hepatic metabolic perturbation of polystyrene nanoplastics by UV irradiation-induced hydroxyl radical generation
Shiyu He, Jingran Wang, Lihong Zhou, Zhen Mao, Xiaodan Zhang, Jin Cai, Peili Huang
Journal of Environmental Sciences.2024; 142: 259. CrossRef Comparable Mortality Between Asian Patients with Chronic Hepatitis B Under Long-Term Antiviral Therapy vs Matched Control: A Population-Based Study
Byungyoon Yun, Juyeon Oh, Sang Hoon Ahn, Jin-Ha Yoon, Beom Kyung Kim
American Journal of Gastroenterology.2023; 118(6): 1001. CrossRef Rhamnetin ameliorates non-alcoholic steatosis and hepatocellular carcinoma in vitro
Mahmoud A. Shatta, Marwa O. El-Derany, Abdullah A. Gibriel, Hala O. El-Mesallamy
Molecular and Cellular Biochemistry.2023; 478(8): 1689. CrossRef Statin use is associated with better post‐operative prognosis among patients with hepatitis B virus‐related hepatocellular carcinoma
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
European Journal of Clinical Investigation.2023;[Epub] CrossRef Association of Fatty Liver Index with Incident Diabetes Risk in Patients Initiating Statin–Therapy: A 6-Year Retrospective Study
Georgia Anastasiou, Evangelos Liberopoulos, Ermioni Petkou, Amalia Despoina Koutsogianni, Petros Spyridwnas Adamidis, George Liamis, Evangelia Ntzani, Fotios Barkas
Diagnostics.2023; 13(3): 503. CrossRef Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
Seung Min Lee, Dae Won Jun
Clinical and Molecular Hepatology.2023; 29(1): 171. CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
Jung Hwan Yu, Han Ah Lee, Seung Up Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S136. CrossRef Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Tina Reinson, Ryan M. Buchanan, Christopher D. Byrne
Clinical and Molecular Hepatology.2023; 29(Suppl): S157. CrossRef Screening strategy for non-alcoholic fatty liver disease
Saisai Zhang, Lung-Yi Mak, Man-Fung Yuen, Wai-Kay Seto
Clinical and Molecular Hepatology.2023; 29(Suppl): S103. CrossRef Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and
future
Terry Cheuk-Fung Yip, Fei Lyu, Huapeng Lin, Guanlin Li, Pong-Chi Yuen, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Clinical and Molecular Hepatology.2023; 29(Suppl): S171. CrossRef Baseline Tyrosine Level Is Associated with Dynamic Changes in FAST Score in NAFLD Patients under Lifestyle Modification
Hwi Young Kim, Da Jung Kim, Hye Ah Lee, Joo-Youn Cho, Won Kim
Metabolites.2023; 13(3): 444. CrossRef Noninvasive serum biomarkers for liver steatosis in nonalcoholic fatty liver disease: Current and future developments
Sang Bong Ahn
Clinical and Molecular Hepatology.2023; 29(Suppl): S150. CrossRef The effects of moderate alcohol consumption on non-alcoholic fatty liver disease
Hyunwoo Oh, Won Sohn, Yong Kyun Cho
Clinical and Molecular Hepatology.2023; 29(Suppl): S261. CrossRef Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima
Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef Non-alcoholic fatty liver disease: the pathologist’s perspective
Wei-Qiang Leow, Anthony Wing-Hung Chan, Paulo Giovanni L. Mendoza, Regina Lo, Kihan Yap, Haeryoung Kim
Clinical and Molecular Hepatology.2023; 29(Suppl): S302. CrossRef Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis
Yi-wen Shi, Jian-Gao Fan
Clinical and Molecular Hepatology.2023; 29(Suppl): S228. CrossRef Eating, diet, and nutrition for the treatment of non-alcoholic fatty liver disease
Georg Semmler, Christian Datz, Michael Trauner
Clinical and Molecular Hepatology.2023; 29(Suppl): S244. CrossRef Bile Acid Alterations Characterize the Early Onset and Progression of Nonalcoholic Fatty Liver Disease in Young Mice Fed with High Fat and Fructose Diet
Wenqing Xiang, Ana Liu, Cuifang Xu, Danni Zhang, Wei Li, Yan Ni
Molecular Nutrition & Food Research.2023;[Epub] CrossRef A lipidomic study: Nobiletin ameliorates hepatic steatosis through regulation of lipid alternation
Xushan Yang, Linye Sun, Dongliang Feng, Yudi Deng, Wenzhen Liao
The Journal of Nutritional Biochemistry.2023; 118: 109353. CrossRef Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
Alimentary Pharmacology & Therapeutics.2023; 58(2): 229. CrossRef Mass spectrometry-based untargeted metabolomics study of non-obese individuals with non-alcoholic fatty liver disease
Metin Demirel, Fatmanur Köktaşoğlu, Esin Özkan, Halime Dulun Ağaç, Ayşe Zehra Gül, Rasul Sharifov, Ufuk Sarıkaya, Metin Başaranoğlu, Şahabettin Selek
Scandinavian Journal of Gastroenterology.2023; 58(11): 1344. CrossRef Farnesoid X receptor is an important target for the treatment of disorders of bile acid and fatty acid metabolism in mice with nonalcoholic fatty liver disease combined with cholestasis
Xinzhu Liu, Jiaxuan Wang, Maogang Li, Jiannan Qiu, Xingying Li, Li Qi, Jia Liu, Ping Liu, Guoxiang Xie, Xiaoning Wang
Journal of Gastroenterology and Hepatology.2023; 38(8): 1438. CrossRef Fibrotic Burden in the Liver Differs Across Metabolic Dysfunction-Associated Fatty Liver Disease Subtypes
Tae Seop Lim, Ho Soo Chun, Soon Sun Kim, Ja Kyung Kim, Minjong Lee, Hyo Jung Cho, Seung Up Kim, Jae Youn Cheong
Gut and Liver.2023; 17(4): 610. CrossRef Effect of 12-week intermittent calorie restriction compared to standard of care in patients with nonalcoholic fatty liver disease: a randomized controlled trial
Han Ah Lee, Hyeyoung Moon, Yuri Kim, Hye Ah Lee, Hwi Young Kim
Trials.2023;[Epub] CrossRef Bavachin combined with epimedin B induce idiosyncratic liver injury under immunological stress conditions
Mengmeng Lin, Yingying Li, Bo Cao, Jing Xu, Yujun Zhang, Guohui Li, Xiaohe Xiao, Chunyu Li
Chemico-Biological Interactions.2023; 386: 110774. CrossRef Serum metabolomic profiling unveils distinct sex-related metabolic patterns in NAFLD
Charalambos Fotakis, Ioanna-Panagiota Kalafati, Athina I. Amanatidou, Vasiliki Andreou, Manolis Matzapetakis, Maria Kafyra, Iraklis Varlamis, Maria Zervou, George V. Dedoussis
Frontiers in Endocrinology.2023;[Epub] CrossRef Genetically predicted plasma levels of amino acids and metabolic dysfunction-associated fatty liver disease risk: a Mendelian randomization study
Jian Zhao, Jing Zeng, Cairong Zhu, Xuechao Li, Dong Liu, Jun Zhang, Fei Li, Giovanni Targher, Jian-Gao Fan
BMC Medicine.2023;[Epub] CrossRef MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, Mohammed Eslam, Jacob George, Takuji Torimura
Clinical and Molecular Hepatology.2022; 28(2): 150. CrossRef Characteristics of Urine Organic Acid Metabolites in Nonalcoholic Fatty Liver Disease Assessed Using Magnetic Resonance Imaging with Elastography in Korean Adults
Ji-Hee Haam, Yun Kyong Lee, Eunkyung Suh, Young-Sang Kim
Diagnostics.2022; 12(5): 1199. CrossRef Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics
Simona Riccio, Rosa Melone, Caterina Vitulano, Pierfrancesco Guida, Ivan Maddaluno, Stefano Guarino, Pierluigi Marzuillo, Emanuele Miraglia del Giudice, Anna Di Sessa
World Journal of Clinical Pediatrics.2022; 11(3): 221. CrossRef Effect of metabolic dysfunction‐associated fatty liver disease on liver cancer risk in a population with chronic hepatitis B virus infection: A nationwide study
Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin‐Ha Yoon, Beom Kyung Kim
Hepatology Research.2022; 52(12): 975. CrossRef The emerging roles of extracellular vesicles as intercellular messengers in liver physiology and pathology
Youngseok Lee, Jong-Hoon Kim
Clinical and Molecular Hepatology.2022; 28(4): 706. CrossRef The Evidence Surrounding Non-Alcoholic Fatty Liver Disease in Individuals with Cancer: A Systematic Literature Review
Elena S. George, Surbhi Sood, Nicole Kiss, Robin M. Daly, Amanda J. Nicoll, Stuart K. Roberts, Brenton J. Baguley
Current Oncology.2022; 30(1): 48. CrossRef Study on the Hepatoprotection of Schisandra chinensis Caulis Polysaccharides in Nonalcoholic Fatty Liver Disease in Rats Based on Metabolomics
Yanbo Feng, Han Li, Cong Chen, Hao Lin, Guangyu Xu, He Li, Chunmei Wang, Jianguang Chen, Jinghui Sun
Frontiers in Pharmacology.2021;[Epub] CrossRef
|